Gastroenterology clinical outcomes

Clinical outcomes are broadly agreed, measurable changes in health or quality of life that result from our care. Constant review of our clinical outcomes establishes standards against which to continuously improve all aspects of our practice.

About the Gastroenterology Service

The Gastroenterology Service at Great Ormond Street Hospital (GOSH) is one of the UK’s leading centres of excellence in treating complex diseases affecting the gut and other associated organs.  

The team sees over 5,000 children with chronic and life-limiting gut conditions each year, and has pioneered leading edge treatments for previously incurable diseases, including autoimmune paediatric gut disease. 

The department sees more children with life-limiting and life-threatening gut disease than any other centre in the UK. In collaboration with the University College London (UCL) Institute of Child Health, the department is committed to translating excellence in research into effective treatments of gastro-intestinal (GI) disorders in children.

Clinical outcome measures

1.Inflammatory bowel disease (IBD) disease activity and clinical remission

The Gastroenterology Service participates in ImproveCareNow, a United States-based collaboration between 97 Paediatric GI centres internationally, 94 in the USA, two in the UK (including GOSH) and one in Qatar. The collaboration benchmarks improvement in quality and monitors clinical outcomes for children with inflammatory bowel disease.

As part of the ImproveCareNow initiative, we monitor specific IBD outcome measures and have routinely collected data since 2011. These data include outcomes relating to disease remission rates, nutrition and growth for the children we treat.

While there are seasonal and external factors that affect these outcomes, the trend as shown below indicates an increase in inactive patients (those in disease remission) and a decrease in active patients (those whose disease is not in remission), both in total number and in disease severity.

The graph below shows data from March 2011 to May 2017:

Fig 1.1 IBD Disease Activity and Clinical Remission, March 2011 to May 2017

IBD disease activity and clinical remission 2011 to 2017

In May 2017, 73 per cent of our registered patients were in remission, up from 46 per cent in March 2011. In real terms, this means that an additional 45 children are now well and do not need hospitalisation or steroid treatment.

This information was published in July 2017.